Form 4 for ANTX AN2 Therapeutics, Inc.
Accepted 2022-10-24 00:00:00 ET · period of report 2022-10-20 · accession 0000899243-22-034092 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2022-10-24 | 2022-10-20+ | ANTX | Easom Eric | CEO, Dir | S - Sale | $16.47 | -21.2K | 7,257 | -75% | -$349.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-10-20 | S | D | 7,262 | $16.68 | 18,889 | D | — | — | |
| 2 | Common | Common Stock | 2022-10-20 | S | D | 31 | $17.15 | 18,858 | D | — | — | |
| 3 | Common | Common Stock | 2022-10-21 | S | D | 2,350 | $16.69 | 4,907 | D | — | — | |
| 4 | Common | Common Stock | 2022-10-21 | S | D | 11,601 | $16.29 | 7,257 | D | — | — |